Clinical trials: Follow-Up Studies
Sore-throat, Cough
The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study
Demulcent or soothing substance is the currently recommended option to alleviate throat irritation associated to cough and sore throat in children under 6 years.
- Trial name
- Touxpetit (NCT06688370)
- Testing
- Petit Drill
- Where
- France
- Volunteers
- 12 people
- Sponsor
- Pierre Fabre Medicament
Intraosseous Vascular Access
Healthy Adult Volunteer Study of Intraosseous Infusion Using the Sternum
This study is being done to evaluate intraosseous vascular access through the sternum.
- Trial name
- NCT01853215
- Testing
- T.A.L.O.N. Intraosseous System
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vidacare Corporation
Epilepsy, Partial
A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy
Open-label study to allow pediatric patients who have participated in prior Levetiracetam (Keppra®) studies to continue their treatment with adequate monitoring and standardized follow-up care until Levetiracetam (Keppra®) is…
- Trial name
- NCT00150709
- Testing
- Levetiracetam
- Volunteers
- 223 people
- Sponsor
- UCB Pharma
Symptomatic Dermographism
Urticaria Facticia Treatment With Omalizumab (UFO)
Urticaria is a very frequent skin condition characterized by transient wheal and flare type skin reactions associated with severe pruritus.
- Trial name
- UFO (NCT02169115)
- Testing
- Omalizumab
- Where
- 2 sites in Germany
- Volunteers
- 61 people
- Sponsor
- Charite University, Berlin, Germany
Covid19, Critical Care
Impact on Mental, Physical, And Cognitive Functioning of a Critical Care sTay During the COVID-19 Pandemic
Intensive care unit (ICU) survivors and their families frequently present mental, cognitive and physical impairments lasting years. The ongoing pandemic could affect the duration, variety, and severity of these impairments.
- Conditions
- Covid19, Critical Care, Postintensive Care Syndrome
- Trial name
- IMPACCT (NCT04979897)
- Testing
- Intensive care unit stay during the COVID-19 pandemic
- Where
- 7 sites in Chile
- Volunteers
- 252 people
- Sponsor
- Universidad del Desarrollo
Rheumatoid Arthritis
Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
To continue to assess the clinical safety and efficacy of Certolizumab Pegol as add-on therapy with stable-dose Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Trial name
- CERTAIN 2 (NCT00843778)
- Testing
- Certolizumab Pegol
- Where
- 25 sites in Austria, France and 3 more
- Volunteers
- 131 people
- Sponsor
- UCB Pharma
Male Hypogonadism
Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men
The purpose of this one year extension (follow-up) study is to gather additional safety data in hypogonadal men treated with oral TU or AndroGel who have completed the 12-month Phase III study CLAR-09007.
- Trial name
- NCT01699178
- Testing
- Oral testosterone undecanoate, Transdermal testosterone gel (AndroGel)
- Where
- 30 sites in United States, Germany
- Volunteers
- 182 people
- Sponsor
- Clarus Therapeutics, Inc.
Atrial Fibrillation
POLARx Cardiac Cryoablation System Study
This is a Post Market Clinical Follow-up (PMCF) study designed to establish the continued safety and effectiveness profile of the Boston Scientific Cardiac Cryoablation System after receiving CE mark.
- Trial name
- POLAR ICE (NCT04250714)
- Testing
- Boston Scientific Cardiac Cryoablation System
- Where
- 19 sites in Belgium, Croatia and 5 more
- Volunteers
- 400 people
- Sponsor
- Boston Scientific Corporation
Prevention of Acute Rejection in Paediatric Recipients of a Renal Transplant
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
The purpose of this study is to determine if everolimus combined with reduced exposure CNI (TAC) is efficacious and safe and will support corticosteroid elimination compared to a standard exposure CNI (TAC) + MMF + steroid…
- Trial name
- NCT01544491
- Testing
- RAD001, MMF
- Where
- 31 sites in United States, Argentina and 11 more
- Volunteers
- 106 people
- Sponsor
- Novartis Pharmaceuticals
Disaster Medicine, Difficult Intravenous Access
EASI Access II --- Follow-up Study to the EASI Access Trial
Test whether Basic Life Support (BLS) providers can successfully place Enzymatically Augmented Subcutaneous Infusion (EASI) Access lines for subcutaneous infusion, and characterize intravascular absorption of EASI-administered…
- Conditions
- Disaster Medicine, Difficult Intravenous Access, Dehydration
- Trial name
- NCT00740727
- Testing
- Human recombinant hyaluronidase (HRH), Enzymatically Augmented Subcutaneous Infusion (EASI) line placement
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Child Development
The MOM Program: 5 Year Follow-up Study of a Home Visiting Program at The Children's Hospital of Philadelphia
The purpose of the MOM Program Continuation is to promote child development by helping families become more competent in accessing and using available health, developmental and educational resources.
- Trial name
- MOM Program (NCT00231179)
- Testing
- Home visiting professional support model, Control
- Where
- United States
- Volunteers
- 302 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Rheumatoid Arthritis
A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
An open ended study in which patients who completed the preceding double-blind study NCT00160602 are given Certolizumab Pegol and assessed for signs and symptoms of Rheumatoid Arthritis.
- Trial name
- NCT00160641
- Testing
- Certolizumab Pegol
- Where
- 67 sites in United States, Bulgaria and 11 more
- Volunteers
- 567 people
- Sponsor
- UCB Pharma
Glioblastoma, Glioblastoma With Primitive Neuronal Component
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
This phase II trial studies how well whole brain radiation therapy works with standard temozolomide chemo-radiotherapy and plerixafor in treating patients with glioblastoma (brain tumor).
- Conditions
- Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma
- Trial name
- NCT03746080
- Testing
- Plerixafor, Temozolomide, Whole-Brain Radiotherapy (WBRT)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Lawrence D Recht
Osteoarthritis, Hip, Complications; Arthroplasty
Encore Revelation Hip Stem
The purpose of this study is to obtain long-term (10+ yrs) clinical and patient outcomes data on patients who received the Revelation Hip Stem prior to 2002.
- Trial name
- NCT01514318
- Testing
- Revelation Hip Stem (Revelation)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Encore Medical, L.P.
Gouty Arthritis
Long Term Study of Canakinumab (ACZ885) in Patients With Gout
This 24-week open-label extension study is designed to provide additional long-term safety data up to a total of 1-year for patients rolling over from the core study, and to collect further efficacy and tolerability data for all…
- Trial name
- NCT00927810
- Testing
- Canakinumab
- Where
- 45 sites in United States, Argentina and 16 more
- Volunteers
- 341 people
- Sponsor
- Novartis Pharmaceuticals
Rosacea
Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle
This study evaluates the safety and efficacy of once-daily application of CLS001 topical gel compared to vehicle gel in subjects with severe papulopustular rosacea.
- Trial name
- NCT02576860
- Testing
- CLS001 (Omiganan), Vehicle
- Where
- 47 sites in United States, Australia and 7 more
- Volunteers
- 263 people, healthy volunteers welcome
- Sponsor
- Maruho Co., Ltd.
Partially Edentulous Jaw
Study on OsseoSpeed™ TX Short Implants in a Chinese Population
The purpose of this study is to investigate the clinical efficacy of OsseoSpeed™ TX 6 mm implants in a Chinese population by evaluation of marginal bone level alteration, implant stability and implant survival in the posterior…
- Trial name
- NCT01346696
- Testing
- OsseoSpeed™ TX implant (Ø 4.0 mm, length 6 mm)
- Where
- 3 sites in China
- Volunteers
- 45 people
- Sponsor
- Dentsply Sirona Implants and Consumables
Infections, Papillomavirus
Gynaecological Follow-up of a Subset of 580299/008 (NCT00122681) Study Subjects
This study is designed to provide up to four years of annual oncogenic HPV DNA testing and cervical cytology examination for NCT00122681 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV…
- Trial name
- NCT00937950
- Testing
- Gynaecological follow-up
- Where
- 83 sites in United States, Australia and 11 more
- Volunteers
- 2,022 people
- Sponsor
- GlaxoSmithKline
Diabetes, Glycemic Control
The VA Diabetes Trial Follow-up Study (VADT-FS)
CSP #465, "Glycemic Control and Complications in Diabetes Mellitus Type 2," was a randomized unblinded clinical trial comparing tight glycemic control to standard glycemic control.
- Trial name
- VADT-F (NCT00756613)
- Where
- 2 sites in United States
- Volunteers
- 1,044 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Type 2, Hypertension
The Medication Metronome Project - Study to Facilitate Follow-up Testing Resulting From Prescribed Medications to Improve Patient Safety and Care
This project tests a model of chronic disease medication management in which the decision to initiate or adjust medical therapy is directly linked to a sequence of subsequent clinical actions (e.g.
- Conditions
- Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemia
- Trial name
- NCT01586897
- Testing
- Medication Metronome, Usual Care
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Massachusetts General Hospital